The authors wish to thank Arthritis Research UK for convening the meeting as part of the Clinical Studies Group for Osteoarthritis and Crystal Diseases programme. The views of Arthritis Research UK have not influenced the content of this guideline. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.Peer reviewedPublisher PD
Background: Recent innovations in the pharmaceutical drug discovery environment have generated new c...
SummaryThe goal of this document is to update the original OARSI recommendations specifically for th...
Author summary Why was this study done? Hip and knee osteoarthritis is a common chronic joint diseas...
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumat...
OBJECTIVE:Treatment of OA by stratifying for commonly used and novel therapies will likely improve t...
Objective: Treatment of OA by stratifying for commonly used and novel therapies will likely improve ...
Objective. Treatment of OA by stratifying for commonly used and novel therapies will likely improve ...
Objective: Population-based osteoarthritis (OA) cohorts provide vital data on risk factors and outco...
SummaryTo highlight methodologic challenges pertinent to design, analysis, and reporting of results ...
SummaryOsteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulat...
Full list of author information is available at the end of the articleOsteoarthritis (OA) is the mos...
Objective: There are unique challenges to designing and carrying out high quality trials testing the...
Background Osteoarthritis is a heterogeneous condition characterised by a wide variety of factors an...
Objective: To update the 1997 OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Researc...
Background: Osteoarthritis (OA) is the most common long-term condition managed in UK general practic...
Background: Recent innovations in the pharmaceutical drug discovery environment have generated new c...
SummaryThe goal of this document is to update the original OARSI recommendations specifically for th...
Author summary Why was this study done? Hip and knee osteoarthritis is a common chronic joint diseas...
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumat...
OBJECTIVE:Treatment of OA by stratifying for commonly used and novel therapies will likely improve t...
Objective: Treatment of OA by stratifying for commonly used and novel therapies will likely improve ...
Objective. Treatment of OA by stratifying for commonly used and novel therapies will likely improve ...
Objective: Population-based osteoarthritis (OA) cohorts provide vital data on risk factors and outco...
SummaryTo highlight methodologic challenges pertinent to design, analysis, and reporting of results ...
SummaryOsteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulat...
Full list of author information is available at the end of the articleOsteoarthritis (OA) is the mos...
Objective: There are unique challenges to designing and carrying out high quality trials testing the...
Background Osteoarthritis is a heterogeneous condition characterised by a wide variety of factors an...
Objective: To update the 1997 OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Researc...
Background: Osteoarthritis (OA) is the most common long-term condition managed in UK general practic...
Background: Recent innovations in the pharmaceutical drug discovery environment have generated new c...
SummaryThe goal of this document is to update the original OARSI recommendations specifically for th...
Author summary Why was this study done? Hip and knee osteoarthritis is a common chronic joint diseas...